A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lymphoma
Status:
Completed
Trial end date:
2001-04-01
Target enrollment:
Participant gender:
Summary
Patients with CD22(+) B-cell lymphomas will be treated with escalating doses as a 192 hr
infusion of immunotoxin in a Phase I study to determine dose limiting toxicity evidence of
response.